Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Techne (TECH)

Bio-Techne Q4 fiscal 2024 revenue up 2%, but GAAP EPS falls to $0.25 from $0.47

Mixed Impact 3 of 5 earnings Written later

Bio-Techne reported fourth-quarter fiscal 2024 net sales up 2% to $306.1 million, with organic revenue up 1%, while GAAP earnings per share fell to $0.25 from $0.47 a year earlier. Full-year net sales rose 2% to $1.2 billion, but full-year GAAP EPS fell to $1.05 from $1.76, and the company also announced a cash dividend in a separate press release.

Key points

  • Q4 GAAP operating income fell 52% to $45.8 million; adjusted operating income fell 9% to $101.8 million
  • Q4 adjusted EPS was $0.49 versus $0.55 a year earlier; full-year adjusted EPS was $1.77 versus $1.99
  • Diagnostics and Genomics segment Q4 net sales rose 15% to $90.7 million, while Protein Sciences Q4 net sales fell 4% to $214.0 million
  • Full-year cash flow from operations rose 18% to $299.0 million; the filing does not state the dividend amount

The filing

CompanyBio-Techne (TECH)
Form8-K, current report
Filed with the SECAug 7, 2024, 6:32 AM ET
Accession number0001558370-24-011193

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.